secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001104659-24-044767
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma reports positive Phase 3 etripamil data for PSVT self-treatment
--------------------------------------------------------------------------------

- NODE-303 open-label study: etripamil nasal spray restored sinus rhythm with median time-to-conversion 17.0 minutes.
- Efficacy at 30 min was 60%, at 60 min 69.9% — similar to prior double-blinded studies.
- Safety consistent: adverse events mostly localized to nasal administration site; frequency decreased with successive episodes.
- Data presented at ACC 2024 and published in JACC; supports potential shift in PSVT self-management.
- CARDAMYST (conditionally approved brand name) could become first at-the-ready option for acute PSVT if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924044767/0001104659-24-044767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924044767/tm2411306d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-044767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer